Alnylam Pharmaceuticals

To harness RNAi to create new medicines, building a top-tier global biopharma company with a self-sustaining financial profile.

Alnylam Pharmaceuticals SWOT Analysis

Updated: October 4, 2025 • 2025-Q4 Analysis

How to Use This Analysis

This analysis for Alnylam Pharmaceuticals was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.

While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.

Powered by Leading AI Models

Anthropic

Industry-leading reasoning capabilities with 200K context window for comprehensive analysis

Google Gemini

State-of-the-art multimodal intelligence with real-time market data processing and trend analysis

OpenAI GPT

Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities

The Alnylam SWOT analysis reveals a company at a critical inflection point. Its scientific leadership and commercial execution in rare diseases are undisputed strengths, fueling impressive revenue growth. However, this success has created a dependence on its TTR franchise, which faces imminent, formidable competition. The entire enterprise value hinges on flawlessly executing two massive opportunities: the HELIOS-B trial in cardiology and the Zilebesiran launch in hypertension. These moves represent a pivot from a niche leader to a global biopharma powerhouse. The key priorities correctly identify that success requires parallel processing: perfecting near-term blockbuster execution while simultaneously investing in the next wave of scientific innovation (extra-hepatic delivery) and building the global infrastructure to support its immense ambition. The path forward is clear, but the execution risk is substantial.

Ionis Pharmaceuticals BridgeBio Pharma Arrowhead Pharmaceuticals Intellia Therapeutics Moderna

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To harness RNAi to create new medicines, building a top-tier global biopharma company with a self-sustaining financial profile.

Toggle Theme

Strengths

COMMERCIAL: AMVUTTRA's rapid uptake shows exceptional launch execution.
PIPELINE: Zilebesiran hypertension data de-risks move to prevalent disease.
PLATFORM: IKARIA platform enables more durable and potent drug candidates.
FINANCIALS: Growing revenue ($1.24B FY23) puts profitability goal in reach.
PARTNERSHIPS: Roche deal for Zilebesiran validates platform for big markets.

Weaknesses

PROFITABILITY: Significant GAAP net losses persist despite revenue growth.
DEPENDENCE: TTR franchise (AMVUTTRA/ONPATTRO) is over 50% of revenue.
COMPETITION: BridgeBio's ATTR-CM data presents a major competitive risk.
DELIVERY: Extra-hepatic delivery remains a major scientific/clinical hurdle.
SCALE: Lacks established primary care commercial infrastructure for blockbusters.

Opportunities

CARDIOMYOPATHY: HELIOS-B trial readout is a massive binary event for AMVUTTRA.
HYPERTENSION: Zilebesiran targets a >$50B market, a company-making opportunity.
CNS: Early data in CNS/ocular programs could unlock enormous future value.
EXPANSION: Geographic expansion in Asia & LatAm for approved products.
DIAGNOSTICS: Improved genetic screening could vastly expand patient pools.

Threats

COMPETITION: BridgeBio's acoramidis could limit ATTR-CM market share.
PRICING: IRA drug pricing negotiations pose a long-term threat to revenue.
REGULATORY: FDA/EMA hurdles for new indications or novel drug approvals.
EXECUTION: Clinical trial failures, especially in late-stage, are costly.
PAYERS: Increased payer scrutiny on high-cost drugs for large populations.

Key Priorities

EXECUTE: Flawlessly deliver HELIOS-B results and prepare for Zilebesiran.
DIVERSIFY: Aggressively advance non-TTR pipeline assets into late-stage.
SCALE: Build the commercial and manufacturing muscle for prevalent diseases.
INNOVATE: Solve RNAi delivery beyond the liver to unlock the next growth wave.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Alnylam Pharmaceuticals OKR

Updated: October 4, 2025 • 2025-Q4 Analysis

The Alnylam OKR plan is a masterclass in strategic focus, translating SWOT priorities into actionable, ambitious goals. It rightly prioritizes the two massive catalysts—cardiology and hypertension—that will define the company's future. The objectives are inspiring and concise, while the key results are measurable, outcome-driven, and stretch the organization. This plan effectively balances near-term, must-win execution (HELIOS-B, profitability) with crucial investments in long-term growth (non-TTR pipeline, extra-hepatic delivery). By rallying the entire company around these four pillars, this Alnylam OKR framework provides the clarity and alignment needed to navigate its most critical year and complete its transformation into a global biopharma leader.

Ionis Pharmaceuticals BridgeBio Pharma Arrowhead Pharmaceuticals Intellia Therapeutics Moderna

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To harness RNAi to create new medicines, building a top-tier global biopharma company with a self-sustaining financial profile.

WIN IN CARDIOLOGY

Deliver a landmark win in ATTR-CM & launch a new paradigm.

HELIOS-B: Achieve the composite primary endpoint of all-cause mortality and cardiovascular events in the HELIOS-B trial.
LAUNCH: Secure broad payer coverage for AMVUTTRA in ATTR-CM for >70% of US commercial lives within 6 months of approval.
ZILEBESIRAN: Complete enrollment of the KARDIA-3 Phase 3 trial in partnership with Roche ahead of internal schedule.
AWARENESS: Double cardiologist-driven genetic testing for TTR via a targeted 'Think TTR' educational campaign.

EXPAND BEYOND TTR

Advance our next wave of transformative medicines to patients.

IND: File 2 new Investigational New Drug (IND) applications for programs targeting extra-hepatic (non-liver) tissues.
ENROLLMENT: Complete patient enrollment for the KARDIA-1 Phase 3 trial for cemdisiran in IgA nephropathy.
DATA: Announce positive top-line data from a mid-stage clinical program in a new, non-TTR therapeutic area.
PARTNERSHIP: Establish one new strategic R&D collaboration to gain access to a novel delivery technology or target class.

BUILD FOR SCALE

Forge the infrastructure for a top-tier global biopharma.

PROFITABILITY: Achieve full-year 2025 non-GAAP profitability for the first time in company history, demonstrating sustainability.
MANUFACTURING: Qualify a second large-scale manufacturing site for Zilebesiran to ensure launch supply chain redundancy.
COMMERCIAL: Establish the core U.S. primary care field leadership team in preparation for the Zilebesiran launch.
DIGITAL: Reduce patient onboarding time by 30% through the launch of a new, unified patient services digital platform.

PIONEER NEW FRONTIERS

Unlock new tissues to bring RNAi to more diseases.

CNS: Nominate the first clinical development candidate targeting a CNS disease for formal IND-enabling toxicology studies.
DELIVERY: Demonstrate >75% target gene knockdown in a second non-liver tissue (e.g., muscle) in non-human primates.
PLATFORM: Advance a novel, internal platform technology (e.g., new siRNA chemistry) into formal preclinical testing.
TALENT: Attract and hire a world-renowned scientific leader to head a new research unit for extra-hepatic delivery.

METRICS

Total Product Net Revenue: $1.85B
Non-GAAP Profitability: Achieve Positive Net Income
Late-Stage Pipeline Readouts: 2 Positive Phase 3 Trials

VALUES

Commitment to People
Innovation and Discovery
Sense of Urgency
Open Culture
Passion for Excellence

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Alnylam Pharmaceuticals Retrospective

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Ionis Pharmaceuticals BridgeBio Pharma Arrowhead Pharmaceuticals Intellia Therapeutics Moderna

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To harness RNAi to create new medicines, building a top-tier global biopharma company with a self-sustaining financial profile.

Toggle Theme

What Went Well

COMMERCIAL: AMVUTTRA global net product sales exceeded consensus estimates.
FINANCIAL: Maintained discipline on OpEx, keeping P5x25 profitability goal on track.
PIPELINE: Positive Zilebesiran KARDIA-2 data met all primary & secondary endpoints.
PARTNERSHIPS: Achieved key milestones in Roche collaboration, triggering payments.
STRATEGY: Clear, consistent communication of strategy resonated with investors.

Not So Well

COMPETITION: Increased investor questions on BridgeBio's competitive threat.
GUIDANCE: Conservative forward-looking guidance may have tempered enthusiasm.
OXLUMO: Slower than anticipated growth for OXLUMO in key European markets.
SENTIMENT: Broader biotech market headwinds (XBI) continue to affect valuation.
R&D: A minor delay was announced for an early-stage pipeline program.

Learnings

EXECUTION: The market rewards strong commercial execution above all else.
COMMUNICATION: Proactive communication on the competitive landscape is critical.
DIVERSIFICATION: Investors are keenly focused on pipeline progress beyond TTR.
PROFITABILITY: The path to profitability is a key driver of shareholder value.
DATA: High-quality clinical data is the best answer to competitive noise.

Action Items

HELIOS-B: Develop a comprehensive communication plan for the HELIOS-B data release.
ZILEBESIRAN: Finalize Phase 3 plans and manufacturing scale-up with Roche.
INVESTORS: Host a specific investor event focused on the non-TTR pipeline.
COMMERCIAL: Implement new initiatives to accelerate OXLUMO patient identification.
FINANCE: Refine financial models to provide enhanced clarity on path to profit.

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Explore specialized team insights and strategies

Alnylam Pharmaceuticals Market

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Founded: 2002
Market Share: Dominant in RNAi; leading share in hATTR amyloidosis and AHP.
Customer Base: Patients with specific rare genetic diseases; expanding to prevalent conditions.
Category:
Biotechnology
SIC Code: 2834
NAICS Code: 325414 Biological Product (except Diagnostic) Manufacturing
Location: Cambridge, Massachusetts
Zip Code: 02142 Boston, Massachusetts
Congressional District: MA-7 BOSTON
Employees: 2100

Competitors

Ionis Pharmaceuticals View Analysis

BridgeBio Pharma View Analysis

Arrowhead Pharmaceuticals View Analysis

Intellia Therapeutics View Analysis

Moderna View Analysis

Products & Services

No products or services data available

Distribution Channels

Alnylam Pharmaceuticals Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Problem

Genetic diseases lack effective treatments
Progressive organ damage and early mortality
High burden of care for patients/families

Solution

RNAi drugs that silence disease-causing genes
Targeted, highly effective therapies
Infrequent dosing (quarterly, semi-annually)

Key Metrics

Net product revenue growth
Number of patients on therapy
Late-stage pipeline advancements

Unique

Pioneering and leading RNAi therapeutics
Proprietary GalNAc delivery platform
Deep expertise in genetics and biology

Advantage

Broad and deep intellectual property portfolio
First-mover advantage in multiple diseases
Regulatory success and commercial infrastructure

Channels

Specialty sales force, Key Account Managers
Medical Science Liaisons (MSLs)
Partnerships with academic centers

Customer Segments

Patients with rare genetic diseases
Specialist physicians (e.g. neurologists)
Hospital systems and payers

Costs

High R&D investment in clinical trials
Sales, General & Administrative (SG&A) costs
Contract manufacturing (CMO) expenses

Alnylam Pharmaceuticals Product Market Fit Analysis

Updated: October 4, 2025

Alnylam silences the genes that cause devastating diseases. By precisely targeting the genetic root cause, its RNAi medicines deliver transformative outcomes, halting or even reversing disease progression. This proven platform is creating a new class of predictable, life-changing therapies for patients who previously had little hope, unlocking immense value for patients and the healthcare system.

TARGETED: Precisely silencing the genetic root cause of devastating diseases.

TRANSFORMATIVE: Halting or reversing disease progression with profound clinical outcomes.

PREDICTABLE: A proven platform for developing a new wave of genetic medicines.

Before State

Living with progressive, debilitating diseases
Limited or no effective treatment options
Symptomatic management, not root cause
Constant genetic disease progression

After State

Disease progression halted or reversed
Targeted treatment at the genetic source
Improved clinical outcomes and quality of life
Hope for a manageable, long-term future

Negative Impacts

Poor quality of life and organ damage
High burden on patients and caregivers
Shortened life expectancy, constant anxiety
Significant healthcare system costs

Positive Outcomes

Reduced hospitalizations and complications
Increased patient independence and function
Long-term value for the healthcare system
Transforming fatal diseases into chronic ones

Key Metrics

Patient adherence/retention rates >90%

Net Promoter Score (NPS) estimated >60 among physicians

New patient starts growth rate >20% YoY for key products

G2 Reviews

N/A (Pharmaceutical)

High repeat purchase rates (subscription-like for chronic diseases)

Requirements

Accurate genetic diagnosis of patients
Physician education on new therapies
Securing broad market access and reimbursement
Robust patient support and services

Why Alnylam Pharmaceuticals

Targeting genes with high confidence
Efficient, reproducible RNAi platform
Focused commercial execution in specialty areas
Strong patient advocacy group partnerships

Alnylam Pharmaceuticals Competitive Advantage

First-mover and leader in RNAi therapeutics
Proprietary delivery tech to the liver
Decades of focused scientific expertise
Deep relationships with key opinion leaders

Proof Points

Multiple FDA/EMA approved transformative drugs
Consistent, positive pivotal trial data
Strong real-world evidence post-launch
Thousands of patients treated globally

Alnylam Pharmaceuticals Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Strategic pillars derived from our vision-focused SWOT analysis

Lead in RNAi science and platform innovation.

Aggressively advance from rare to prevalent diseases.

Maximize launch success and global market access.

Achieve non-GAAP profitability and growth.

What You Do

Develop and commercialize RNAi therapeutics that silence disease-causing genes.

Target Market

Patients with genetically-defined diseases and their treating specialists.

Differentiation

Pioneering RNAi science and delivery
Robust, self-originated pipeline
Proven global commercial capabilities

Revenue Streams

Direct product sales
Royalties (e.g., Leqvio)
Partnership and collaboration fees

Alnylam Pharmaceuticals Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Company Operations

Organizational Structure: Functional structure with therapeutic area focus in R&D and commercial.
Supply Chain: Relies on contract manufacturing organizations (CMOs) for drug substance/product.
Tech Patents: Extensive patent estate covering fundamental aspects of RNAi technology.
Website: https://www.alnylam.com

Top Clients

Board Members

Alnylam Pharmaceuticals Competitive Forces

Threat of New Entry

LOW: Extremely high barriers to entry due to massive R&D costs, complex science, extensive patent estates, and regulatory hurdles.

Supplier Power

MODERATE: Specialized CMOs for oligonucleotide synthesis have some leverage, but Alnylam is a major customer, mitigating this power.

Buyer Power

HIGH: Concentrated buyers (insurers, national health systems) exert significant pricing pressure due to the high cost of therapies.

Threat of Substitution

MODERATE to HIGH: Other modalities like gene therapy, gene editing (CRISPR), and small molecules are potential long-term substitutes.

Competitive Rivalry

MODERATE: High in TTR-amyloidosis (Ionis, BridgeBio), but low in other rare diseases where Alnylam is often first-in-class.

Analysis of AI Strategy

Updated: October 4, 2025 • 2025-Q4 Analysis

The Alnylam AI SWOT Analysis underscores a pivotal opportunity to amplify its core competitive advantage. Alnylam is not a tech company, but its business is built on a mountain of high-quality, structured biological data—a perfect substrate for AI. The primary opportunity is not just operational efficiency, but strategic acceleration. By embedding AI into its discovery engine, Alnylam can increase the speed and probability of success in identifying new drug targets and designing better molecules, widening its moat against competitors. The key priorities correctly focus on integrating data, optimizing clinical trials, and accelerating the core R&D process. Winning requires treating AI not as a separate IT project, but as a fundamental enhancement to its pioneering biological platform, turning a data-rich company into an insight-driven one.

Ionis Pharmaceuticals BridgeBio Pharma Arrowhead Pharmaceuticals Intellia Therapeutics Moderna

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To harness RNAi to create new medicines, building a top-tier global biopharma company with a self-sustaining financial profile.

Strengths

DATA: Decades of proprietary genomic, preclinical, and clinical trial data.
PLATFORM: Core siRNA design process is already computationally intensive.
EXPERTISE: Strong existing bioinformatics and computational biology teams.
VALIDATION: Clinical outcomes provide high-quality labels for training models.
FOCUS: Genetically-defined targets provide clear inputs for AI discovery.

Weaknesses

TALENT: Fierce competition for top-tier AI/ML scientists with deep biology PhDs.
INFRASTRUCTURE: Legacy data silos may hinder development of integrated AI models.
SCALE: Current computational resources may be insufficient for large models.
CULTURE: Integrating AI-driven insights into a traditional R&D process is hard.
BIAS: Limited diversity in early trial data could create biased AI algorithms.

Opportunities

DISCOVERY: AI to accelerate novel target identification and siRNA sequence design.
TRANSLATION: Predict preclinical to human translation to reduce failure rates.
TRIALS: Optimize clinical trial design and patient selection for higher success.
COMMERCIAL: AI-driven analytics to identify undiagnosed patients from EMR data.
MANUFACTURING: Use AI to optimize CMC processes and improve manufacturing yields.

Threats

COMPETITION: Tech-first biotechs (e.g., Recursion) may innovate faster.
IP: Ambiguity around intellectual property for AI-generated drug candidates.
REGULATORY: FDA/EMA scrutiny of AI/ML models used in pivotal drug development.
RELIABILITY: 'Black box' nature of some AI models can be a risk for GxP.
SECURITY: Increased cybersecurity risks for valuable proprietary data sets.

Key Priorities

ACCELERATE: Systematically deploy AI/ML to shorten drug discovery timelines.
OPTIMIZE: Use AI predictive models to increase clinical trial success rates.
INTEGRATE: Build a unified data architecture to power AI across the enterprise.
PERSONALIZE: Explore AI for patient stratification and personalized dosing.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Alnylam Pharmaceuticals Financial Performance

AI-Powered Insights

Claude

Gemini

GPT

Alnylam Pharmaceuticals Q4 2023 Earnings Report and 10-K Filing
Alnylam Investor Day Presentations (2023/2024)
Corporate website (alnylam.com) for mission, values, and leadership
Press releases related to clinical trial data (Zilebesiran, HELIOS-B)
Third-party financial data providers for market cap and stock information
Industry analysis from publications like FiercePharma and BioPharma Dive

Profit: FY 2023 Net Loss: ($922.7M)

Market Cap: $20.5 Billion (as of early 2024)

Stock Performance

Annual Report: Available on Alnylam's investor relations website

Debt: Total Liabilities: ~$3.1 Billion (Q4 2023)

ROI Impact: High R&D spend impacts current ROI, but successful launches promise future returns.

SWOT Index

Composite strategic assessment with 10-year outlook

/ 100

Category Leader

ICM Index

STRATEGIC ADVISOR ASSESSMENT

Alnylam's score reflects its position as a category creator at a pivotal moment. The high Ambition (societal impact of RNAi) is tempered by significant execution risk, reflected in a solid but not stellar Achievability score. The SWOT is balanced, with massive opportunities (Zilebesiran) offset by potent threats (BridgeBio). OKRs are strong but focused on category-shaping rather than world-shaping goals for now. The growth multiplier indicates strong potential, contingent on navigating near-term competitive and clinical hurdles.

SWOT Factors

Upside: 83.3 Risk: 80.0

OKR Impact

AI Leverage

Top 3 Strategic Levers

EXECUTE: Deliver a decisive win in the HELIOS-B trial.

DIVERSIFY: Accelerate the non-TTR pipeline to mitigate risk.

INNOVATE: Solve extra-hepatic delivery to unlock the platform.

AI Disclosure

This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.

Next Step

Want to see how the Alignment Method could surface unique insights for your business?

Request your custom report Contact our team

About Alignment LLC

Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.